<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drug\PMC7352498\results\search\disease\results.xml">
  <result pre="7352498 doi: 10.3390/nano10061072nanomaterials-10-01072 : Review Nanomaterials and Nanotechnology-Associated Innovations against" exact="Viral" post="Infections with a Focus on Coronaviruses https://orcid.org/0000-0002-4539-3544NasrollahzadehMahmoud1*SajjadiMohaddeseh1https://orcid.org/0000-0002-0441-7247SoufiGhazaleh Jamalipour2https://orcid.org/0000-0003-3985-7928IravaniSiavash3*https://orcid.org/0000-0001-9731-6228VarmaRajender S.4*[1],"/>
  <result pre="doi: 10.3390/nano10061072nanomaterials-10-01072 : Review Nanomaterials and Nanotechnology-Associated Innovations against Viral" exact="Infections" post="with a Focus on Coronaviruses https://orcid.org/0000-0002-4539-3544NasrollahzadehMahmoud1*SajjadiMohaddeseh1https://orcid.org/0000-0002-0441-7247SoufiGhazaleh Jamalipour2https://orcid.org/0000-0003-3985-7928IravaniSiavash3*https://orcid.org/0000-0001-9731-6228VarmaRajender S.4*[1], mhd.sajjadi@gmail.com[2],"/>
  <result pre="of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). Abstract" exact="Viral" post="infections have recently emerged not only as a health"/>
  <result pre="the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). Abstract Viral" exact="infections" post="have recently emerged not only as a health threat"/>
  <result pre="rapid diagnostic detection and therapeutic interventional options against the caused" exact="infections" post="including vaccine development for prevention and control. Coronaviruses, namely"/>
  <result pre="resolve the critical issues regarding detection, prevention, and treatment of" exact="viral" post="infections. This perspective review expounds recent nanoscience advancements for"/>
  <result pre="expounds recent nanoscience advancements for the detection and treatment of" exact="viral" post="infections with focus on coronaviruses and encompasses nano-based formulations"/>
  <result pre="recent nanoscience advancements for the detection and treatment of viral" exact="infections" post="with focus on coronaviruses and encompasses nano-based formulations and"/>
  <result pre="SARS-CoV-2. nanotechnology nanoparticles quantum dots graphene oxide nanovaccines coronaviruses COVID-19" exact="viral" post="infections SARS-CoV-2 1. Introduction Presently, the outbreak of viral"/>
  <result pre="nanotechnology nanoparticles quantum dots graphene oxide nanovaccines coronaviruses COVID-19 viral" exact="infections" post="SARS-CoV-2 1. Introduction Presently, the outbreak of viral respiratory"/>
  <result pre="COVID-19 viral infections SARS-CoV-2 1. Introduction Presently, the outbreak of" exact="viral" post="respiratory infections is rampant and spreading all over the"/>
  <result pre="viral infections SARS-CoV-2 1. Introduction Presently, the outbreak of viral" exact="respiratory" post="infections is rampant and spreading all over the world,"/>
  <result pre="infections SARS-CoV-2 1. Introduction Presently, the outbreak of viral respiratory" exact="infections" post="is rampant and spreading all over the world, and"/>
  <result pre="host cell, whose interactions with them mostly include receptor-ligand interactions;" exact="respiratory" post="viruses, among them, represent serious threats for all demographics."/>
  <result pre="drug design and discovery is prompted by inherent characteristics of" exact="viral" post="illnesses that contain complexities in lifecycle stages, main alterations"/>
  <result pre="compartments, development of drug resistance, and the feasibility of latent" exact="viral" post="infections in an inaccessible biological compartment, among others. The"/>
  <result pre="development of drug resistance, and the feasibility of latent viral" exact="infections" post="in an inaccessible biological compartment, among others. The quick"/>
  <result pre="last 20â€‰years, few old illnesses have re-emerged, and many new" exact="infectious disease" post="agents, especially viruses, have appeared, with human immunodeficiency virus"/>
  <result pre="20â€‰years, few old illnesses have re-emerged, and many new infectious" exact="disease" post="agents, especially viruses, have appeared, with human immunodeficiency virus"/>
  <result pre="new infectious disease agents, especially viruses, have appeared, with human" exact="immunodeficiency" post="virus (HIV) and acute respiratory infections being the leading"/>
  <result pre="especially viruses, have appeared, with human immunodeficiency virus (HIV) and" exact="acute" post="respiratory infections being the leading causes of death worldwide"/>
  <result pre="viruses, have appeared, with human immunodeficiency virus (HIV) and acute" exact="respiratory" post="infections being the leading causes of death worldwide [1,2,3,4]."/>
  <result pre="have appeared, with human immunodeficiency virus (HIV) and acute respiratory" exact="infections" post="being the leading causes of death worldwide [1,2,3,4]. Owing"/>
  <result pre="of pathogenic viruses, the lack of immunization and therapy of" exact="infectious" post="illnesses have become a critical challenge and a clinical"/>
  <result pre="a critical challenge and a clinical threat in an exceedingly" exact="short" post="span of time. The human respiratory mucosa is the"/>
  <result pre="threat in an exceedingly short span of time. The human" exact="respiratory" post="mucosa is the most significant portal and the primary"/>
  <result pre="in an exceedingly short span of time. The human respiratory" exact="mucosa" post="is the most significant portal and the primary site"/>
  <result pre="human respiratory mucosa is the most significant portal and the" exact="primary" post="site of entry for incursion or infection by various"/>
  <result pre="portal and the primary site of entry for incursion or" exact="infection" post="by various viruses such as the influenza virus, the"/>
  <result pre="infection by various viruses such as the influenza virus, the" exact="respiratory" post="syncytial virus, and the parainfluenza virus, among others. These"/>
  <result pre="parainfluenza virus, among others. These virulent pathogens initially infect the" exact="upper" post="respiratory tract and then reach the lower breathing airways"/>
  <result pre="virus, among others. These virulent pathogens initially infect the upper" exact="respiratory" post="tract and then reach the lower breathing airways (or"/>
  <result pre="initially infect the upper respiratory tract and then reach the" exact="lower" post="breathing airways (or lower respiratory tract), leading to death."/>
  <result pre="respiratory tract and then reach the lower breathing airways (or" exact="lower" post="respiratory tract), leading to death. Lower respiratory tract illnesses"/>
  <result pre="tract and then reach the lower breathing airways (or lower" exact="respiratory" post="tract), leading to death. Lower respiratory tract illnesses explicate"/>
  <result pre="breathing airways (or lower respiratory tract), leading to death. Lower" exact="respiratory" post="tract illnesses explicate a leading cause of human morbidity"/>
  <result pre="spread through direct contact or droplets/aerosols, effectively replicate in the" exact="respiratory" post="tract, and mostly cause clinical symptoms/manifestations, namely fever, dyspnea,"/>
  <result pre="mostly cause clinical symptoms/manifestations, namely fever, dyspnea, cough, bronchiolitis, and/or" exact="pneumonia" post="[6]. Most respiratory tract infections are due to one"/>
  <result pre="symptoms/manifestations, namely fever, dyspnea, cough, bronchiolitis, and/or pneumonia [6]. Most" exact="respiratory" post="tract infections are due to one of the numerous"/>
  <result pre="fever, dyspnea, cough, bronchiolitis, and/or pneumonia [6]. Most respiratory tract" exact="infections" post="are due to one of the numerous respiratory viruses,"/>
  <result pre="respiratory tract infections are due to one of the numerous" exact="respiratory" post="viruses, mostly influenza virus, respiratory syncytial virus (RSV), rhinovirus"/>
  <result pre="to one of the numerous respiratory viruses, mostly influenza virus," exact="respiratory" post="syncytial virus (RSV), rhinovirus (RV), and severe/acute respiratory syndrome"/>
  <result pre="influenza virus, respiratory syncytial virus (RSV), rhinovirus (RV), and severe/acute" exact="respiratory" post="syndrome (SARS), infecting the personâ€™s lower respiratory tract [7,8,9,10]."/>
  <result pre="virus, respiratory syncytial virus (RSV), rhinovirus (RV), and severe/acute respiratory" exact="syndrome" post="(SARS), infecting the personâ€™s lower respiratory tract [7,8,9,10]. Nevertheless,"/>
  <result pre="rhinovirus (RV), and severe/acute respiratory syndrome (SARS), infecting the personâ€™s" exact="lower" post="respiratory tract [7,8,9,10]. Nevertheless, adenovirus, parainfluenza virus, enterovirus, and"/>
  <result pre="(RV), and severe/acute respiratory syndrome (SARS), infecting the personâ€™s lower" exact="respiratory" post="tract [7,8,9,10]. Nevertheless, adenovirus, parainfluenza virus, enterovirus, and human"/>
  <result pre="play relevant roles, especially during epidemics [11]. Most of these" exact="infections" post="(~80%) are caused by the viruses summarized in Figure"/>
  <result pre="the viruses summarized in Figure 1 and Figure 2 [9]." exact="Respiratory" post="viruses generally present a main health issue in infants,"/>
  <result pre="people, and/or immunocompromised patients. Parainfluenza virus [13] and/or RSV [14]" exact="infections" post="are the leading causes of hospitalization for acute respiratory"/>
  <result pre="RSV [14] infections are the leading causes of hospitalization for" exact="acute" post="respiratory illnesses in children, leading to 40% and 45%"/>
  <result pre="[14] infections are the leading causes of hospitalization for acute" exact="respiratory" post="illnesses in children, leading to 40% and 45% of"/>
  <result pre="to 40% and 45% of pediatric hospitalizations, respectively. Among these" exact="viral" post="infections, 3~5% of the lower respiratory tract illness cases"/>
  <result pre="pediatric hospitalizations, respectively. Among these viral infections, 3~5% of the" exact="lower" post="respiratory tract illness cases in children are caused by"/>
  <result pre="hospitalizations, respectively. Among these viral infections, 3~5% of the lower" exact="respiratory" post="tract illness cases in children are caused by adenovirus"/>
  <result pre="respiratory tract illness cases in children are caused by adenovirus" exact="infections" post="[15]. SARS, the most recent infectious illness, is generally"/>
  <result pre="are caused by adenovirus infections [15]. SARS, the most recent" exact="infectious" post="illness, is generally an acute form of bronchopneumonia, which"/>
  <result pre="[15]. SARS, the most recent infectious illness, is generally an" exact="acute" post="form of bronchopneumonia, which could be caused by a"/>
  <result pre="CoVs are the main pathogens that primarily target the human" exact="respiratory" post="system. The first emergence of â€œSARS-CoVâ€� infections (8-month outbreak)"/>
  <result pre="target the human respiratory system. The first emergence of â€œSARS-CoVâ€�" exact="infections" post="(8-month outbreak) had a fatality rate of ~10%, which"/>
  <result pre="cases [10]. In 2012, after ten years, the Middle East" exact="respiratory" post="syndrome â€œ(MERS)-CoVâ€� emerged in a universal outbreak, which was"/>
  <result pre="[10]. In 2012, after ten years, the Middle East respiratory" exact="syndrome" post="â€œ(MERS)-CoVâ€� emerged in a universal outbreak, which was transmitted"/>
  <result pre="2019-nCoV (emerging novel CoV), as a potentially deadly â€œSARS-CoV-2â€� (severe/acute" exact="respiratory" post="syndrome CoV 2) presented a critical threat and a"/>
  <result pre="(emerging novel CoV), as a potentially deadly â€œSARS-CoV-2â€� (severe/acute respiratory" exact="syndrome" post="CoV 2) presented a critical threat and a global"/>
  <result pre="and a global concern to vulnerable populations within an extremely" exact="short" post="time span [16]. Astoundingly, these emerging SARS-CoVs are more"/>
  <result pre="elderly population, particularly those who suffer from hypertension, diabetes, and" exact="cardiovascular" post="or coronary heart illness. At least half of these"/>
  <result pre="those who suffer from hypertension, diabetes, and cardiovascular or coronary" exact="heart" post="illness. At least half of these patients are tremendously"/>
  <result pre="susceptible to infection, which may turn into a cytokine storm," exact="septic shock," post="metabolic acidosis coagulation dysfunction, acute respiratory distress syndrome (ARDS),"/>
  <result pre="infection, which may turn into a cytokine storm, septic shock," exact="metabolic acidosis" post="coagulation dysfunction, acute respiratory distress syndrome (ARDS), heading to"/>
  <result pre="which may turn into a cytokine storm, septic shock, metabolic" exact="acidosis" post="coagulation dysfunction, acute respiratory distress syndrome (ARDS), heading to"/>
  <result pre="into a cytokine storm, septic shock, metabolic acidosis coagulation dysfunction," exact="acute" post="respiratory distress syndrome (ARDS), heading to demise. We are"/>
  <result pre="a cytokine storm, septic shock, metabolic acidosis coagulation dysfunction, acute" exact="respiratory" post="distress syndrome (ARDS), heading to demise. We are today"/>
  <result pre="storm, septic shock, metabolic acidosis coagulation dysfunction, acute respiratory distress" exact="syndrome" post="(ARDS), heading to demise. We are today witnessing a"/>
  <result pre="HIV [19,20]. Indeed, the main challenges to combat such epidemic" exact="viral" post="infections are that for several of them (especially SARS-CoV"/>
  <result pre="[19,20]. Indeed, the main challenges to combat such epidemic viral" exact="infections" post="are that for several of them (especially SARS-CoV infections)"/>
  <result pre="possibly only way to diminish public health challenges resulting from" exact="viral" post="illnesses. Efforts to control these respiratory infections are focused"/>
  <result pre="health challenges resulting from viral illnesses. Efforts to control these" exact="respiratory" post="infections are focused on prevention via vaccine advancement. This"/>
  <result pre="challenges resulting from viral illnesses. Efforts to control these respiratory" exact="infections" post="are focused on prevention via vaccine advancement. This perspective"/>
  <result pre="novel nanovaccine transfer platforms and useful nanodrugs for treatment of" exact="viral infection." post="2. Nanotechnology against Viral Infections with Focus on CoVs"/>
  <result pre="useful nanodrugs for treatment of viral infection. 2. Nanotechnology against" exact="Viral" post="Infections with Focus on CoVs Nanotechnology and nanoscience refers"/>
  <result pre="nanodrugs for treatment of viral infection. 2. Nanotechnology against Viral" exact="Infections" post="with Focus on CoVs Nanotechnology and nanoscience refers to"/>
  <result pre="without exposing the healthy tissue cells, sensitive imaging to detect" exact="viral" post="illnesses at early stages, and crossing these barriers (e.g.,"/>
  <result pre="functionalized multi-walled carbon nanotube comprising photo-activated molecules) and inhibition of" exact="viral" post="binding with the host cell surface receptor are important"/>
  <result pre="is thus a significant requirement for the remediation of virus" exact="infections" post="since numerous antiviral nanodrugs are essential to ensure they"/>
  <result pre="(e.g., HIV integrase, which is responsible for the attachment of" exact="viral" post="DNA into host/cell chromosomes) [26]. Other unmet enquiries in"/>
  <result pre="viral DNA into host/cell chromosomes) [26]. Other unmet enquiries in" exact="viral" post="management options comprise the utilization of RNA-mediated interference technology,"/>
  <result pre="promising molecular tactic for the handling of a variety of" exact="infectious" post="illnesses [27]. Indeed, there are limitations that prohibit validity"/>
  <result pre="of siRNA within or onto the NPs/nanocarriers could attain successful" exact="viral" post="replication inhibition; developments of efficient and novel treatment approaches"/>
  <result pre="curcumin modified silver NPs had a remarkable inhibitory effect against" exact="respiratory" post="syncytial virus (RSV) infection [29]. Nanotechnology-based platforms for nanotherapeutic"/>
  <result pre="had a remarkable inhibitory effect against respiratory syncytial virus (RSV)" exact="infection" post="[29]. Nanotechnology-based platforms for nanotherapeutic drugs that are successfully"/>
  <result pre="successfully approved or under further investigation for treating or inhibiting" exact="viral" post="infections are summarized in Table 1. Additionally, some significant"/>
  <result pre="approved or under further investigation for treating or inhibiting viral" exact="infections" post="are summarized in Table 1. Additionally, some significant engineered"/>
  <result pre="nanomaterials have attained favorable stature to alter the cycle of" exact="viral infection" post="[60]. The virus entrance into the host cells might"/>
  <result pre="have attained favorable stature to alter the cycle of viral" exact="infection" post="[60]. The virus entrance into the host cells might"/>
  <result pre="addition of ligands on their surfaces may thus meddle with" exact="viral" post="connection and block its entrance into cells [57]. In"/>
  <result pre="among MERS-CoV and host cells, the main conduit for host" exact="infections" post="induced by MERS-CoV [61]. Mainly, the inhibitory influences of"/>
  <result pre="by MERS-CoV [61]. Mainly, the inhibitory influences of peptide pregnancy-prompted" exact="hypertension" post="have been accelerated 10-fold by generation of a gold"/>
  <result pre="triangular star-shaped bovine serum albumin (BSA)-coated tellurium NPs reportedly suppressed" exact="virus infection" post="predominantly by obstructing the virus internalization procedure; these nanostars"/>
  <result pre="star-shaped bovine serum albumin (BSA)-coated tellurium NPs reportedly suppressed virus" exact="infection" post="predominantly by obstructing the virus internalization procedure; these nanostars"/>
  <result pre="procedure; these nanostars showed remarkable antiviral activities against porcine epidemic" exact="diarrhea" post="virus (PEDV) (e.g., CoV) [62]. 2.1. Nano-Based Advances for"/>
  <result pre="diarrhea virus (PEDV) (e.g., CoV) [62]. 2.1. Nano-Based Advances for" exact="Viral" post="Detection With the evident possibility of enormous outbreaks, the"/>
  <result pre="variability of several viruses. In addition, the traditional techniques for" exact="respiratory" post="virus detection are generally costly, time consuming, labor intensive,"/>
  <result pre="on pathogenic viruses and are geared up for detection of" exact="viral" post="infections. In this respect, gold (Au) NPs and quantum"/>
  <result pre="components in the improvement/advancement of novel nanotechnology-based detection for several" exact="respiratory" post="viruses; Au NPs have been combined with silver staining"/>
  <result pre="for the detection of HPV (human papillomavirus) in a cervical" exact="carcinoma" post="cell [65]. Currently, there is an array of nanostructures,"/>
  <result pre="which can include biomolecules (one or more) derived from viruses." exact="Antibody" post="(Ab), DNA, RNA, antigen, etc. are conjugated on the"/>
  <result pre="Interestingly, in one study, a double-operational plasmonic biosensor merging the" exact="localized" post="surface plasmon resonance (LSPR) sensing transduction and the plasmonic"/>
  <result pre="for Designing Vaccines The disruptive outbreaks of fatal epidemics and" exact="respiratory" post="infectious illnesses have greatly uplifted the progress of modern"/>
  <result pre="Designing Vaccines The disruptive outbreaks of fatal epidemics and respiratory" exact="infectious" post="illnesses have greatly uplifted the progress of modern and"/>
  <result pre="of the most extraordinary tactics for preventing, controlling, or ameliorating" exact="infectious diseases," post="as well as administrating the antigenic materials to motivate"/>
  <result pre="of numerous potentially fatal illnesses, such as polio, smallpox, measles," exact="hepatitis" post="A, papilloma, etc. Despite numerous efforts, many other illnesses"/>
  <result pre="vaccines towards numerous clinically relevant viruses, e.g., HIV, Zika viruses," exact="hepatitis C" post="viruses (HCVs), influenza virus (e.g., H5N1, H1N1, etc.), cytomegaloviruses"/>
  <result pre="6 present the general timelines for the vaccine development against" exact="viral" post="infections [72], including the year when given viruses started"/>
  <result pre="present the general timelines for the vaccine development against viral" exact="infections" post="[72], including the year when given viruses started transmitting"/>
  <result pre="that has been shown to work particularly well for a" exact="viral" post="vector or nucleic acid-based vaccines. For HIV, in 1983"/>
  <result pre="immunization have recently contributed to improvements in the efficacy of" exact="viral" post="vaccines, amongst which the emerging nanotechnology holds enormous promise"/>
  <result pre="platforms (Table 5). In this respect, VLPs provide repetitive immunodominant" exact="viral" post="epitopes to improve the activation of a particular, robust"/>
  <result pre="the protective efficacy of nanocarrier/NPs against viruses that exploit diverse" exact="infection" post="routes are required to be improved and better characterized."/>
  <result pre="carbohydrates, among others), or modular functionalization by the fabrication of" exact="stable" post="structures could all lead to improved drug delivery and"/>
  <result pre="diversity of directing moieties (e.g., antibodies) allows the transport of" exact="viral" post="antigens directly to particular surface receptors, thus inciting specific"/>
  <result pre="control, and fight against infections, especially those leading to several" exact="respiratory" post="or pulmonary diseases. To date, vaccine formulations include subunit"/>
  <result pre="fight against infections, especially those leading to several respiratory or" exact="pulmonary" post="diseases. To date, vaccine formulations include subunit protein antigens,"/>
  <result pre="the CoV transmembrane spike (S) glycoprotein, which extends from the" exact="viral" post="surface and mediates host cell entry [121]. SARS-CoV-2 S"/>
  <result pre="to provide a blueprint for designing vaccines and inhibitors of" exact="viral" post="entrance. SARS-CoV S murine polyclonal antibodies effectively obstructed SARS-CoV-2"/>
  <result pre="may be a promising and effective prophylactic approach against MERS-CoV" exact="infection" post="[87]. In one investigation, by expressing the structural proteins"/>
  <result pre="prepared. Consequently, the spike S protein of MERS-CoV came up" exact="short" post="on its transmembrane, and the cytoplasmic areas (SÎ&quot;TM) were"/>
  <result pre="0.5â€‰Âµg S protein without escape of adjuvant from SARS after" exact="infection" post="with mouse-adapted SARSâ€&quot;CoV; however, eosinophilic infiltrations were detected in"/>
  <result pre="of adjuvant from SARS after infection with mouse-adapted SARSâ€&quot;CoV; however," exact="eosinophilic" post="infiltrations were detected in the lungs of the mice"/>
  <result pre="was unsuccessful in improving the efficiency of vaccine or reducing" exact="eosinophilic" post="infiltration, due to significantly allergic inflammatory responses. While comparable"/>
  <result pre="animals immunized with S protein with or without gold NPs," exact="Type 1" post="interferon and pro-inflammatory replies were reasonable in the mice"/>
  <result pre="Toll-like receptor agonist-adjuvanted vaccine triggered remarkable protective antibodies deprived of" exact="eosinophilic" post="infiltrations, in addition to responses of Th1/17 cytokine [50]."/>
  <result pre="of Th1/17 cytokine [50]. 2.3. QDs and GO against CoVs" exact="Infections" post="QDs can be employed as perfect alternatives against pathogenic"/>
  <result pre="of the CQDs with entry receptors of HCoV-229E; additionally, the" exact="viral" post="replication step also displayed similarly big inhibition activity (Figure"/>
  <result pre="The cytotoxicity of the prepared QDs was evaluated against rat" exact="brain" post="glioma C6 cells using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. The"/>
  <result pre="cytotoxicity of the prepared QDs was evaluated against rat brain" exact="glioma" post="C6 cells using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. The anti-infectious"/>
  <result pre="glioma C6 cells using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. The anti-infectious" exact="bronchitis" post="virus (IBV) antibodies of CoV were linked to these"/>
  <result pre="fluorescence characteristics of the nanohybrids (immuno-conjugated QD-magneto-plasmonic NPs) via the" exact="external" post="magnetic field-prompted partition process provided biosensing of CoVs (detection"/>
  <result pre="antiviral activities of graphene oxide (GO) against the porcine epidemic" exact="diarrhea" post="virus (PEDV, an RNA virus) and pseudorabies virus (PRV,"/>
  <result pre="a DNA virus) have been evaluated; GO remarkably inhibited the" exact="infection" post="of these viruses, at non-cytotoxic concentrations, for a 2"/>
  <result pre="energy, were employed to inhibit entry into host cells for" exact="respiratory" post="syndrome and porcine reproductive virus (~59% inhibition). Additionally, this"/>
  <result pre="were employed to inhibit entry into host cells for respiratory" exact="syndrome" post="and porcine reproductive virus (~59% inhibition). Additionally, this nanocomposite"/>
  <result pre="Current Challenges and Future Prospects The incorporation of nanoscience for" exact="infectious disease" post="treatment offers novel opportunities to overcome existing challenges of"/>
  <result pre="Challenges and Future Prospects The incorporation of nanoscience for infectious" exact="disease" post="treatment offers novel opportunities to overcome existing challenges of"/>
  <result pre="diseases, where entrance to unreachable compartments, namely viruses crossing the" exact="blood-brain barrier," post="is obligatory for preventing the creation of dormant infections"/>
  <result pre="blood-brain barrier, is obligatory for preventing the creation of dormant" exact="infections" post="with persistent replication at low levels [133]. Nanoparticulate drug"/>
  <result pre="architecture, or specific properties; they have been therefore developed for" exact="viral" post="detection or treatment and are adequately capable of surmounting"/>
  <result pre="against viruses by different mechanisms, making them attractive tools for" exact="viral" post="treatment. All immunological assets and benefits of nanostructures can"/>
  <result pre="nanostructures possess other exceptional properties, namely their capability to deliver" exact="viral" post="antigens in a controlled manner, their capacities to mimic"/>
  <result pre="diagnosis, treatment, control/management, prevention, and detection, such as nanocarriers for" exact="viral" post="infections and delivery of nanodrugs or bioactive compounds. Consequently,"/>
  <result pre="treatment, control/management, prevention, and detection, such as nanocarriers for viral" exact="infections" post="and delivery of nanodrugs or bioactive compounds. Consequently, nanodrug"/>
  <result pre="delivery systems and nanovaccines are making an actual revolution in" exact="viral" post="disease prevention, treatment, and management; nanotechnology offers new prospects"/>
  <result pre="systems and nanovaccines are making an actual revolution in viral" exact="disease" post="prevention, treatment, and management; nanotechnology offers new prospects towards"/>
  <result pre="for human consumption. For some viruses, including SARS-CoVs, RSV, and" exact="acquired immunodeficiency syndrome" post="(HIV/AIDS), no effective vaccines are presently accessible making infection"/>
  <result pre="human consumption. For some viruses, including SARS-CoVs, RSV, and acquired" exact="immunodeficiency" post="syndrome (HIV/AIDS), no effective vaccines are presently accessible making"/>
  <result pre="consumption. For some viruses, including SARS-CoVs, RSV, and acquired immunodeficiency" exact="syndrome" post="(HIV/AIDS), no effective vaccines are presently accessible making infection"/>
  <result pre="immunodeficiency syndrome (HIV/AIDS), no effective vaccines are presently accessible making" exact="infection" post="detection and treatment a critical necessity. Today, three viruses,"/>
  <result pre="many facts regarding virulence, pathogenesis, and the real source of" exact="viral infection" post="or mode of transmission still need to be addressed;"/>
  <result pre="facts regarding virulence, pathogenesis, and the real source of viral" exact="infection" post="or mode of transmission still need to be addressed;"/>
  <result pre="[17]. For instance, silver NPs showed inhibition abilities against the" exact="viral" post="entrance in host cells, for HIV-1 virus, as these"/>
  <result pre="performed for drug delivery platforms, imaging, and detection systems for" exact="viral" post="localization and specific tissue or organ targeting. Development of"/>
  <result pre="(with high biocompatibility and drug loading) for the mitigation of" exact="uncontrolled" post="inflammation is very promising, especially in the case of"/>
  <result pre="then encapsulating Î±-tocopherol, a natural antioxidant [150]. By using the" exact="vascular" post="endothelial barrier dysfunction at sites of acute inflammation, these"/>
  <result pre="By using the vascular endothelial barrier dysfunction at sites of" exact="acute" post="inflammation, these multidrug NPs could transport the therapeutic agents"/>
  <result pre="could serve as an innovative method for the treatment of" exact="acute" post="inflammation with reduced side effects and significant therapeutic potential,"/>
  <result pre="4. Conclusions Nanomaterials can be considered as perfect candidates against" exact="viral" post="infections, especially CoVs, because of their ability to enter"/>
  <result pre="to enter cells easily and interact with viruses and avoid" exact="viral" post="genome replication. NPs can be applied as a measure"/>
  <result pre="and Control-Volume I.SpringerBerlin, Germany2014205218 2.QasimM.LimD.-J.ParkH.NaD.Nanotechnology for diagnosis and treatment of" exact="infectious" post="diseasesJ. Nanosci. Nanotechnol.2014147374738710.1166/jnn.2014.957825942798 3.WejseC.PatscheC.B.KÃ¼hleA.BambaF.J.V.MendesM.S.LemvikG.GomesV.F.RudolfF.Impact of HIV-1, HIV-2, and HIV-1+"/>
  <result pre="Nanosci. Nanotechnol.2014147374738710.1166/jnn.2014.957825942798 3.WejseC.PatscheC.B.KÃ¼hleA.BambaF.J.V.MendesM.S.LemvikG.GomesV.F.RudolfF.Impact of HIV-1, HIV-2, and HIV-1+ 2 dual" exact="infection" post="on the outcome of tuberculosisInt. J. Infect. Dis.20153212813410.1016/j.ijid.2014.12.01525499041 4.BradenC.R.DowellS.F.JerniganD.B.HughesJ.M.Progress"/>
  <result pre="in global surveillance and response capacity 10 years after severe" exact="acute" post="respiratory syndromeEmerg. Infect. Dis.20131986410.3201/eid1906.13019223731871 5.collab: World Health OrganizationWorld Health"/>
  <result pre="global surveillance and response capacity 10 years after severe acute" exact="respiratory" post="syndromeEmerg. Infect. Dis.20131986410.3201/eid1906.13019223731871 5.collab: World Health OrganizationWorld Health Statistics"/>
  <result pre="SDGs Sustainable Development GoalsWorld Health OrganizationGeneva, Switzerland2016 6.KutterJ.S.SpronkenM.I.FraaijP.L.FouchierR.A.M.HerfstS.Transmission routes of" exact="respiratory" post="viruses among humansCurr. Opin. Virol.20182814215110.1016/j.coviro.2018.01.00129452994 7.PaviaA.T.Viral infections of the"/>
  <result pre="6.KutterJ.S.SpronkenM.I.FraaijP.L.FouchierR.A.M.HerfstS.Transmission routes of respiratory viruses among humansCurr. Opin. Virol.20182814215110.1016/j.coviro.2018.01.00129452994 7.PaviaA.T.Viral" exact="infections" post="of the lower respiratory tract: Old viruses, new viruses,"/>
  <result pre="respiratory viruses among humansCurr. Opin. Virol.20182814215110.1016/j.coviro.2018.01.00129452994 7.PaviaA.T.Viral infections of the" exact="lower" post="respiratory tract: Old viruses, new viruses, and the role"/>
  <result pre="viruses among humansCurr. Opin. Virol.20182814215110.1016/j.coviro.2018.01.00129452994 7.PaviaA.T.Viral infections of the lower" exact="respiratory" post="tract: Old viruses, new viruses, and the role of"/>
  <result pre="new viruses, and the role of diagnosisClin. Infect. Dis.201152S284S28910.1093/cid/cir04321460286 8.WalkerT.A.KhuranaS.TildenS.J.Viral" exact="respiratory" post="infectionsPediatric Clin. North Am.1994411365138110.1016/S0031-3955(16)38876-9 9.CojocaruF.-D.BotezatD.GardikiotisI.UrituC.-M.DodiG.TrandafirL.RezusC.RezusE.TambaB.-I.MihaiC.-T.Nanomaterials designed for antiviral drug"/>
  <result pre="drug delivery transport across biological barriersPharmaceutics20201217110.3390/pharmaceutics12020171 10.WongS.S.Y.YuenK.-Y.The management of coronavirus" exact="infections" post="with particular reference to SARSJ. Antimicrob. Chemother.20086243744110.1093/jac/dkn24318565970 11.PrincipiN.PirallaA.ZampieroA.BianchiniS.UmbrelloG.ScalaA.BosisS.FossaliE.BaldantiF.EspositoS.Bocavirus infection"/>
  <result pre="coronavirus infections with particular reference to SARSJ. Antimicrob. Chemother.20086243744110.1093/jac/dkn24318565970 11.PrincipiN.PirallaA.ZampieroA.BianchiniS.UmbrelloG.ScalaA.BosisS.FossaliE.BaldantiF.EspositoS.Bocavirus" exact="infection" post="in otherwise healthy children with respiratory diseasePLoS ONE20151010.1371/journal.pone.0135640 12.GorbalenyaA.E.BakerS.C.BaricR.S.de"/>
  <result pre="SARSJ. Antimicrob. Chemother.20086243744110.1093/jac/dkn24318565970 11.PrincipiN.PirallaA.ZampieroA.BianchiniS.UmbrelloG.ScalaA.BosisS.FossaliE.BaldantiF.EspositoS.Bocavirus infection in otherwise healthy children with" exact="respiratory" post="diseasePLoS ONE20151010.1371/journal.pone.0135640 12.GorbalenyaA.E.BakerS.C.BaricR.S.de GrootR.J.DrostenC.GulyaevaA.A.HaagmansB.I.IauberC.IeontovichA.M.NeumanB.W.et al.The species Severe acute respiratory"/>
  <result pre="healthy children with respiratory diseasePLoS ONE20151010.1371/journal.pone.0135640 12.GorbalenyaA.E.BakerS.C.BaricR.S.de GrootR.J.DrostenC.GulyaevaA.A.HaagmansB.I.IauberC.IeontovichA.M.NeumanB.W.et al.The species" exact="Severe" post="acute respiratory syndrome-related coronavirus: Classifying 2019-nCoV and naming it"/>
  <result pre="children with respiratory diseasePLoS ONE20151010.1371/journal.pone.0135640 12.GorbalenyaA.E.BakerS.C.BaricR.S.de GrootR.J.DrostenC.GulyaevaA.A.HaagmansB.I.IauberC.IeontovichA.M.NeumanB.W.et al.The species Severe" exact="acute" post="respiratory syndrome-related coronavirus: Classifying 2019-nCoV and naming it SARS-CoV-2Nat."/>
  <result pre="with respiratory diseasePLoS ONE20151010.1371/journal.pone.0135640 12.GorbalenyaA.E.BakerS.C.BaricR.S.de GrootR.J.DrostenC.GulyaevaA.A.HaagmansB.I.IauberC.IeontovichA.M.NeumanB.W.et al.The species Severe acute" exact="respiratory" post="syndrome-related coronavirus: Classifying 2019-nCoV and naming it SARS-CoV-2Nat. Microbiol.2020510.1038/s41564-41020-40695-z"/>
  <result pre="SARS-CoV-2Nat. Microbiol.2020510.1038/s41564-41020-40695-z 13.BrancheA.R.FalseyA.R.Parainfluenza virus infectionSemin. Resp. Crit. Care Med.201653855410.1055/s-0036-158479827486735 14.MazurN.I.HigginsD.NunesM.C.MeleroJ.A.LangedijkA.C.HorsleyN.BuchholzU.J.OpenshawP.J.McLellanJ.S.EnglundJ.A.The" exact="respiratory" post="syncytial virus vaccine landscape: Lessons from the graveyard and"/>
  <result pre="and promising candidatesLancet Infect. Dis.201818e295e31110.1016/S1473-3099(18)30292-529914800 15.LuM.-P.MaL.-Y.ZhengQ.DongL.-L.ChenZ.-M.Clinical characteristics of adenovirus associated" exact="lower" post="respiratory tract infection in childrenWorld J. Pediatrics2013934634910.1007/s12519-013-0431-324235068 16.MunsterV.J.KoopmansM.van DoremalenN.van"/>
  <result pre="promising candidatesLancet Infect. Dis.201818e295e31110.1016/S1473-3099(18)30292-529914800 15.LuM.-P.MaL.-Y.ZhengQ.DongL.-L.ChenZ.-M.Clinical characteristics of adenovirus associated lower" exact="respiratory" post="tract infection in childrenWorld J. Pediatrics2013934634910.1007/s12519-013-0431-324235068 16.MunsterV.J.KoopmansM.van DoremalenN.van RielD.de"/>
  <result pre="Infect. Dis.201818e295e31110.1016/S1473-3099(18)30292-529914800 15.LuM.-P.MaL.-Y.ZhengQ.DongL.-L.ChenZ.-M.Clinical characteristics of adenovirus associated lower respiratory tract" exact="infection" post="in childrenWorld J. Pediatrics2013934634910.1007/s12519-013-0431-324235068 16.MunsterV.J.KoopmansM.van DoremalenN.van RielD.de WitE.A novel"/>
  <result pre="J. Med.200234738539410.1056/NEJMoa01355212167680 20.MasekoS.B.NatarajanS.SharmaV.BhattacharyyaN.GovenderT.SayedY.MaguireG.E.M.LinJ.KrugerH.G.Purification and characterization of naturally occurring HIV-1 (South" exact="African" post="subtype C) protease mutants from inclusion bodiesProtein Expr. Purif.2016122909610.1016/j.pep.2016.02.01326917227"/>
  <result pre="of small interfering RNAs with vitamin E-coupled nanoparticles for treating" exact="hepatitis" post="CSci. Rep.201662486710.1038/srep2486727113197 29.YangX.X.LiC.M.HuangC.Z.Curcumin modified silver nanoparticles for highly efficient"/>
  <result pre="Rep.201662486710.1038/srep2486727113197 29.YangX.X.LiC.M.HuangC.Z.Curcumin modified silver nanoparticles for highly efficient inhibition of" exact="respiratory" post="syncytial virus infectionNanoscale201683040304810.1039/C5NR07918G26781043 30.LiY.LinZ.ZhaoM.GuoM.XuT.WangC.XiaH.ZhuB.Reversal of H1N1 influenza virus-induced apoptosis"/>
  <result pre="with HDAC plus protease inhibitors activate latent HIV and inhibit" exact="viral" post="spreadNanoscale Res. Lett.2015101810.1186/s11671-015-1112-z25977644 40.SankarV.KeerthiM.L.ParmarN.Formation and In-vitro Evaluation of Zidovudine-Lamivudine"/>
  <result pre="41.FiandraL.ColomboM.MazzucchelliS.TruffiM.SantiniB.AlleviR.NebuloniM.CapettiA.RizzardiniG.ProsperiD.Nanoformulation of antiretroviral drugs enhances their penetration across the blood" exact="brain" post="barrier in miceNanomed. Nanotechnol. Biol. Med.2015111387139710.1016/j.nano.2015.03.009 42.DonalisioM.LeoneF.CivraA.SpagnoloR.OzerO.LemboD.CavalliR.Acyclovir-loaded chitosan nanospheres"/>
  <result pre="immunosensor for the corona virus associated with the Middle East" exact="respiratory" post="syndrome using an array of gold nanoparticle-modified carbon electrodesMikrochim."/>
  <result pre="for the corona virus associated with the Middle East respiratory" exact="syndrome" post="using an array of gold nanoparticle-modified carbon electrodesMikrochim. Acta201918622410.1007/s00604-019-3345-530847572"/>
  <result pre="S protein induces a strong antigen-specific IgG response against severe" exact="acute" post="respiratory syndrome-related coronavirus infection, but fails to induce protective"/>
  <result pre="protein induces a strong antigen-specific IgG response against severe acute" exact="respiratory" post="syndrome-related coronavirus infection, but fails to induce protective antibodies"/>
  <result pre="coronavirus infection, but fails to induce protective antibodies and limit" exact="eosinophilic" post="infiltration in lungsMicrobiol. Immunol.202064335110.1111/1348-0421.1275431692019 51.TingD.DongN.FangL.LuJ.BiJ.XiaoS.HanH.Multisite Inhibitors for Enteric Coronavirus:"/>
  <result pre="Mater.201815451545910.1021/acsanm.8b00779 52.DuT.LiangJ.DongN.LuJ.FuY.FangL.XiaoS.HanH.Glutathione-Capped Ag2S Nanoclusters Inhibit Coronavirus Proliferation through Blockage of" exact="Viral" post="RNA Synthesis and BuddingACS Appl. Mater. Interfaces2018104369437810.1021/acsami.7b1381129337529 53.AhmedS.R.KangS.W.OhS.LeeJ.NeethirajanS.Chiral zirconium"/>
  <result pre="SyndromsJ. Antimicrob. Chemother.2016713340335010.1093/jac/dkw33827585965 55.UyekiT.M.ErlandsonK.J.KorchG.Oâ€™HaraM.WathenM.Hu-PrimmerJ.HojvatS.StemmyE.J.DonabedianA.Evelopment of Medical Countermeasures to Middle East" exact="Respiratory" post="Syndrome CoronavirusEmerg. Infect. Dis.2016221610.3201/eid2207.16002226694983 56.ZumlaA.ChanJ.F.W.AzharE.I.HuiD.S.C.YuenK.-Y.Coronavirus-Drug Discovery and Therapeutic OptionsNat."/>
  <result pre="Antimicrob. Chemother.2016713340335010.1093/jac/dkw33827585965 55.UyekiT.M.ErlandsonK.J.KorchG.Oâ€™HaraM.WathenM.Hu-PrimmerJ.HojvatS.StemmyE.J.DonabedianA.Evelopment of Medical Countermeasures to Middle East Respiratory" exact="Syndrome" post="CoronavirusEmerg. Infect. Dis.2016221610.3201/eid2207.16002226694983 56.ZumlaA.ChanJ.F.W.AzharE.I.HuiD.S.C.YuenK.-Y.Coronavirus-Drug Discovery and Therapeutic OptionsNat. Rev201615327347"/>
  <result pre="Opin. Ther. Targets20172113114310.1080/14728222.2017.127141527936982 59.LuL.LiuQ.ZhuY.ChanK.-H.QinL.LiY.WangQ.ChanJ.F.W.DuL.YuF.et al.Sructures-Based Discovery Of Middle East Repiratory" exact="Syndrome" post="Coronavirus Fusion InhibitorNat. Commun.20145115 60.SzuneritsS.BarrasA.KhanalM.PagneuxQ.BoukherroubR.Nanostructures for the Inhibition of"/>
  <result pre="Syndrome Coronavirus Fusion InhibitorNat. Commun.20145115 60.SzuneritsS.BarrasA.KhanalM.PagneuxQ.BoukherroubR.Nanostructures for the Inhibition of" exact="Viral" post="InfectionsMolecules201520140511408110.3390/molecules20081405126247927 61.HuangX.LiM.XuY.ZhangJ.MengX.AnX.SunL.GuoL.ShanX.GeJ.et al.Novel Gold Nanorod-Based HR1 Peptide Inhibitor for"/>
  <result pre="61.HuangX.LiM.XuY.ZhangJ.MengX.AnX.SunL.GuoL.ShanX.GeJ.et al.Novel Gold Nanorod-Based HR1 Peptide Inhibitor for Middle East" exact="Respiratory" post="Syndrome CoronavirusACS Appl. Mater. Interfaces201911197991980710.1021/acsami.9b0424031099550 62.ZhouY.JiangX.TongT.FangL.WuY.LiangJ.XiaoS.High antiviral activity of"/>
  <result pre="al.Novel Gold Nanorod-Based HR1 Peptide Inhibitor for Middle East Respiratory" exact="Syndrome" post="CoronavirusACS Appl. Mater. Interfaces201911197991980710.1021/acsami.9b0424031099550 62.ZhouY.JiangX.TongT.FangL.WuY.LiangJ.XiaoS.High antiviral activity of mercaptoethane"/>
  <result pre="in virus detectionTheranostics20188198510.7150/thno.2385629556369 70.QiuG.GaiZ.TaoY.SchmittJ.Kullak-UblickG.A.WangJ.Dual-Functional Plasmonic Photothermal Biosensors for Highly Accurate" exact="Severe" post="Acute Respiratory Syndrome Coronavirus 2 DetectionACS Nano.202010.1021/acsnano.0c02439 71.SeoG.LeeG.KimM.J.BaekS.H.ChoiM.KuK.B.LeeC.S.JunS.ParkD.KimH.G.et al.Rapid"/>
  <result pre="virus detectionTheranostics20188198510.7150/thno.2385629556369 70.QiuG.GaiZ.TaoY.SchmittJ.Kullak-UblickG.A.WangJ.Dual-Functional Plasmonic Photothermal Biosensors for Highly Accurate Severe" exact="Acute" post="Respiratory Syndrome Coronavirus 2 DetectionACS Nano.202010.1021/acsnano.0c02439 71.SeoG.LeeG.KimM.J.BaekS.H.ChoiM.KuK.B.LeeC.S.JunS.ParkD.KimH.G.et al.Rapid Detection"/>
  <result pre="detectionTheranostics20188198510.7150/thno.2385629556369 70.QiuG.GaiZ.TaoY.SchmittJ.Kullak-UblickG.A.WangJ.Dual-Functional Plasmonic Photothermal Biosensors for Highly Accurate Severe Acute" exact="Respiratory" post="Syndrome Coronavirus 2 DetectionACS Nano.202010.1021/acsnano.0c02439 71.SeoG.LeeG.KimM.J.BaekS.H.ChoiM.KuK.B.LeeC.S.JunS.ParkD.KimH.G.et al.Rapid Detection of"/>
  <result pre="70.QiuG.GaiZ.TaoY.SchmittJ.Kullak-UblickG.A.WangJ.Dual-Functional Plasmonic Photothermal Biosensors for Highly Accurate Severe Acute Respiratory" exact="Syndrome" post="Coronavirus 2 DetectionACS Nano.202010.1021/acsnano.0c02439 71.SeoG.LeeG.KimM.J.BaekS.H.ChoiM.KuK.B.LeeC.S.JunS.ParkD.KimH.G.et al.Rapid Detection of COVID-19"/>
  <result pre="for coronavirus vaccines: A graphical guideNature202058057657710.1038/d41586-020-01221-y32346146 74.ShangW.YangY.RaoY.RaoX.The outbreak of SARS-CoV-2" exact="pneumonia" post="calls for viral vaccinesNPJ Vaccin.2020510.1038/s41541-020-0170-0 75.AmanatF.KrammerF.SARS-CoV-2 Vaccines: Status ReportImmunity20205258358910.1016/j.immuni.2020.03.00732259480"/>
  <result pre="A graphical guideNature202058057657710.1038/d41586-020-01221-y32346146 74.ShangW.YangY.RaoY.RaoX.The outbreak of SARS-CoV-2 pneumonia calls for" exact="viral" post="vaccinesNPJ Vaccin.2020510.1038/s41541-020-0170-0 75.AmanatF.KrammerF.SARS-CoV-2 Vaccines: Status ReportImmunity20205258358910.1016/j.immuni.2020.03.00732259480 76.Thanh LeT.AndreadakisZ.KumarA.GÃ³mez RomÃ¡nR.TollefsenS.SavilleM.MayhewS.The"/>
  <result pre="lymphocytesInfect. Immun.2001697550755810.1128/IAI.69.12.7550-7558.200111705932 78.SahaA.ChowdhuryM.I.NazimM.AlamM.M.AhmedT.HossainM.B.HoreS.K.SultanaG.N.N.SvennerholmA.-M.QadriF.Vaccine specific immune response to an inactivated oral" exact="cholera" post="vaccine and EPI vaccines in a high and low"/>
  <result pre="a double-stranded RNA adjuvant protects mice and ferrets against H5N1" exact="avian influenza" post="in oral delivery modelsClin. Vaccine Immunol.201320859410.1128/CVI.00552-1223155123 80.EpsteinJ.E.TewariK.LykeK.E.SimB.K.L.BillingsleyP.F.LaurensM.B.GunasekeraA.ChakravartyS.JamesE.R.SedegahM.Live attenuated malaria"/>
  <result pre="avian influenza in oral delivery modelsClin. Vaccine Immunol.201320859410.1128/CVI.00552-1223155123 80.EpsteinJ.E.TewariK.LykeK.E.SimB.K.L.BillingsleyP.F.LaurensM.B.GunasekeraA.ChakravartyS.JamesE.R.SedegahM.Live attenuated" exact="malaria" post="vaccine designed to protect through hepatic CD8+ T cell"/>
  <result pre="IgA, and Th17 responses to vaccine antigensInfect. Immun.2012802426243510.1128/IAI.00181-1222526674 82.Tevi-BenissanM.C.MoturiE.AnyaB.-P.M.AschalewT.DickyA.B.NyemboP.A.MbuluL.K.OkeibunorJ.MihigoR.ZawairaF.Contribution of" exact="polio" post="eradication initiative to effective new vaccine introduction in Africa,"/>
  <result pre="initiative to effective new vaccine introduction in Africa, 2010â€&quot;2015Vaccine2016345193519810.1016/j.vaccine.2016.05.06327396517 83.NuismerS.L.AlthouseB.M.MayR.BullJ.J.StrombergS.P.AntiaR.Eradicating" exact="infectious disease" post="using weakly transmissible vaccinesProc. Biol. Sci.20162832016190310.1098/rspb.2016.190327798311 84.StaroverovS.A.VidyashevaI.V.GabalovK.P.VasilenkoO.A.LaskavyiV.N.DykmanL.A.Immunostimulatory effect of"/>
  <result pre="to effective new vaccine introduction in Africa, 2010â€&quot;2015Vaccine2016345193519810.1016/j.vaccine.2016.05.06327396517 83.NuismerS.L.AlthouseB.M.MayR.BullJ.J.StrombergS.P.AntiaR.Eradicating infectious" exact="disease" post="using weakly transmissible vaccinesProc. Biol. Sci.20162832016190310.1098/rspb.2016.190327798311 84.StaroverovS.A.VidyashevaI.V.GabalovK.P.VasilenkoO.A.LaskavyiV.N.DykmanL.A.Immunostimulatory effect of"/>
  <result pre="Biol. Sci.20162832016190310.1098/rspb.2016.190327798311 84.StaroverovS.A.VidyashevaI.V.GabalovK.P.VasilenkoO.A.LaskavyiV.N.DykmanL.A.Immunostimulatory effect of gold nanoparticles conjugated with transmissible" exact="gastroenteritis" post="virusBull. Exp. Biol. Med.201115143610.1007/s10517-011-1350-822448360 85.KimY.S.SonA.KimJ.KwonS.B.KimM.H.KimP.KimJ.ByunY.H.SungJ.LeeJ.et al.Chaperna-Mediated Assembly of Ferritin-Based"/>
  <result pre="Exp. Biol. Med.201115143610.1007/s10517-011-1350-822448360 85.KimY.S.SonA.KimJ.KwonS.B.KimM.H.KimP.KimJ.ByunY.H.SungJ.LeeJ.et al.Chaperna-Mediated Assembly of Ferritin-Based Middle East" exact="Respiratory" post="Syndrome-Coronavirus NanoparticlesFront. Immunol.20189109310.3389/fimmu.2018.0109329868035 86.LinL.C.W.HuangC.Y.YaoB.Y.LinJ.C.AgrawalA.AlgaissiA.PengB.H.LiuY.H.HuangP.H.JuangR.H.et al.Viromimetic STING agonist-loaded hollow polymeric"/>
  <result pre="polymeric nanoparticles for safe and effective vaccination against Middle East" exact="respiratory" post="syndrome coronavirusAdv. Funct. Mater.201929180761610.1002/adfm.20180761632313544 87.JungS.Y.KangK.W.LeeE.Y.SeoD.W.KimH.L.KimH.KwonT.ParkH.L.KimH.LeeS.M.et al.Heterologous primeâ€&quot;boost vaccination with"/>
  <result pre="nanoparticles for safe and effective vaccination against Middle East respiratory" exact="syndrome" post="coronavirusAdv. Funct. Mater.201929180761610.1002/adfm.20180761632313544 87.JungS.Y.KangK.W.LeeE.Y.SeoD.W.KimH.L.KimH.KwonT.ParkH.L.KimH.LeeS.M.et al.Heterologous primeâ€&quot;boost vaccination with adenoviral"/>
  <result pre="nanoparticles induces both Th1 and Th2 responses against Middle East" exact="Respiratory" post="syndrome coronavirusVaccine2018363468347610.1016/j.vaccine.2018.04.08229739720 88.BallJ.M.GrahamD.Y.OpekunA.R.GilgerM.A.GuerreroR.A.EstesM.K.Recombinant Norwalk virusâ€&quot;like particles given orally to"/>
  <result pre="induces both Th1 and Th2 responses against Middle East Respiratory" exact="syndrome" post="coronavirusVaccine2018363468347610.1016/j.vaccine.2018.04.08229739720 88.BallJ.M.GrahamD.Y.OpekunA.R.GilgerM.A.GuerreroR.A.EstesM.K.Recombinant Norwalk virusâ€&quot;like particles given orally to volunteers:"/>
  <result pre="Phase I studyGastroenterology1999117404810.1016/S0016-5085(99)70548-210381908 89.GeldmacherA.SkrastinaD.BorisovaG.PetrovskisI.KrÃ¼gerD.H.PumpensP.UlrichR.A hantavirus nucleocapsid protein segment exposed on" exact="hepatitis" post="B virus core particles is highly immunogenic in mice"/>
  <result pre="vaccine carrier for enhancing the antibody response against synthetic foot-and-mouth" exact="disease" post="virus peptideNanotechnology20102119510110.1088/0957-4484/21/19/19510120400818 93.TaoW.HurstB.L.ShakyaA.K.UddinM.J.IngroleR.S.J.Hernandez-SanabriaM.AryaR.P.BimlerL.PaustS.TarbetE.B.Consensus M2e peptide conjugated to gold nanoparticles"/>
  <result pre="cellsJ. Immunol. Method.2010356475910.1016/j.jim.2010.02.009 96.ZhaoK.ChenG.ShiX.-M.GaoT.-T.LiW.ZhaoY.ZhangF.-Q.WuJ.CuiX.WangY.-F.Preparation and efficacy of a live newcastle" exact="disease" post="virus vaccine encapsulated in chitosan nanoparticlesPLoS ONE2012710.1371/journal.pone.005331423285276 97.JesusS.SoaresE.CostaJ.BorchardG.BorgesO.Immune response"/>
  <result pre="combined with mucosal influenza virus hemagglutinin vaccine protects against influenza" exact="virus infection" post="in miceVaccine2009275896590510.1016/j.vaccine.2009.07.03719647814 99.BrightR.A.CarterD.M.DanilukS.ToapantaF.R.AhmadA.GavrilovV.MassareM.PushkoP.MytleN.RoweT.Influenza virus-like particles elicit broader immune responses"/>
  <result pre="with mucosal influenza virus hemagglutinin vaccine protects against influenza virus" exact="infection" post="in miceVaccine2009275896590510.1016/j.vaccine.2009.07.03719647814 99.BrightR.A.CarterD.M.DanilukS.ToapantaF.R.AhmadA.GavrilovV.MassareM.PushkoP.MytleN.RoweT.Influenza virus-like particles elicit broader immune responses"/>
  <result pre="or recombinant hemagglutininVaccine2007253871387810.1016/j.vaccine.2007.01.10617337102 100.ParezN.FourgeuxC.MohamedA.DubuquoyC.PillotM.DeheeA.CharpilienneA.PoncetD.Schwartz-CornilI.Garbarg-ChenonA.Rectal immunization with rotavirus virus-like particles induces" exact="systemic" post="and mucosal humoral immune responses and protects mice against"/>
  <result pre="as novel immunogens: Design and analysis of a prototypic severe" exact="acute" post="respiratory syndrome vaccineChem. Biol. Drug Des.200973536110.1111/j.1747-0285.2008.00746.x19152635 102.BorgesO.Cordeiro-da-SilvaA.TavaresJ.SantarÃ©mN.de SousaA.BorchardG.JungingerH.E.Immune response"/>
  <result pre="novel immunogens: Design and analysis of a prototypic severe acute" exact="respiratory" post="syndrome vaccineChem. Biol. Drug Des.200973536110.1111/j.1747-0285.2008.00746.x19152635 102.BorgesO.Cordeiro-da-SilvaA.TavaresJ.SantarÃ©mN.de SousaA.BorchardG.JungingerH.E.Immune response by"/>
  <result pre="immunogens: Design and analysis of a prototypic severe acute respiratory" exact="syndrome" post="vaccineChem. Biol. Drug Des.200973536110.1111/j.1747-0285.2008.00746.x19152635 102.BorgesO.Cordeiro-da-SilvaA.TavaresJ.SantarÃ©mN.de SousaA.BorchardG.JungingerH.E.Immune response by nasal"/>
  <result pre="Biol. Drug Des.200973536110.1111/j.1747-0285.2008.00746.x19152635 102.BorgesO.Cordeiro-da-SilvaA.TavaresJ.SantarÃ©mN.de SousaA.BorchardG.JungingerH.E.Immune response by nasal delivery of" exact="hepatitis" post="B surface antigen and codelivery of a CpG ODN"/>
  <result pre="and PLGA nanoparticles enhance humoral, mucosal and cytokine responses to" exact="hepatitis" post="B vaccineMol. Pharm.2011840541510.1021/mp100255c21189035 104.RaghuvanshiR.S.KatareY.K.LalwaniK.AliM.M.SinghO.PandaA.K.Improved immune response from biodegradable polymer"/>
  <result pre="vaccineMol. Pharm.2011840541510.1021/mp100255c21189035 104.RaghuvanshiR.S.KatareY.K.LalwaniK.AliM.M.SinghO.PandaA.K.Improved immune response from biodegradable polymer particles entrapping" exact="tetanus" post="toxoid by use of different immunization protocol and adjuvantsInt."/>
  <result pre="dairy calvesBMC Vet. Res.20151122010.1186/s12917-015-0481-y26293453 106.McGillJ.L.KellyS.M.KumarP.SpeckhartS.HaughneyS.L.HenningsonJ.NarasimhanB.SaccoR.E.Efficacy of mucosal polyanhydride nanovaccine against" exact="respiratory" post="syncytial virus infection in the neonatal calfSci. Rep.2018811510.1038/s41598-018-21292-229311619 107.FrancicaJ.R.LynnG.M.LagaR.JoyceM.G.RuckwardtT.J.MorabitoK.M.ChenM.ChaudhuriR.ZhangB.SastryM.Thermoresponsive"/>
  <result pre="Vet. Res.20151122010.1186/s12917-015-0481-y26293453 106.McGillJ.L.KellyS.M.KumarP.SpeckhartS.HaughneyS.L.HenningsonJ.NarasimhanB.SaccoR.E.Efficacy of mucosal polyanhydride nanovaccine against respiratory syncytial" exact="virus infection" post="in the neonatal calfSci. Rep.2018811510.1038/s41598-018-21292-229311619 107.FrancicaJ.R.LynnG.M.LagaR.JoyceM.G.RuckwardtT.J.MorabitoK.M.ChenM.ChaudhuriR.ZhangB.SastryM.Thermoresponsive polymer nanoparticles co-deliver"/>
  <result pre="Res.20151122010.1186/s12917-015-0481-y26293453 106.McGillJ.L.KellyS.M.KumarP.SpeckhartS.HaughneyS.L.HenningsonJ.NarasimhanB.SaccoR.E.Efficacy of mucosal polyanhydride nanovaccine against respiratory syncytial virus" exact="infection" post="in the neonatal calfSci. Rep.2018811510.1038/s41598-018-21292-229311619 107.FrancicaJ.R.LynnG.M.LagaR.JoyceM.G.RuckwardtT.J.MorabitoK.M.ChenM.ChaudhuriR.ZhangB.SastryM.Thermoresponsive polymer nanoparticles co-deliver"/>
  <result pre="mucosal polyanhydride nanovaccine against respiratory syncytial virus infection in the" exact="neonatal" post="calfSci. Rep.2018811510.1038/s41598-018-21292-229311619 107.FrancicaJ.R.LynnG.M.LagaR.JoyceM.G.RuckwardtT.J.MorabitoK.M.ChenM.ChaudhuriR.ZhangB.SastryM.Thermoresponsive polymer nanoparticles co-deliver RSV F trimers"/>
  <result pre="L.)Vaccine20123065666710.1016/j.vaccine.2011.10.10522100638 112.KumarA.MaH.ZhangX.HuangK.JinS.LiuJ.WeiT.CaoW.ZouG.LiangX.-J.Gold nanoparticles functionalized with therapeutic and targeted peptides for" exact="cancer" post="treatmentBiomaterials2012331180118910.1016/j.biomaterials.2011.10.05822056754 113.McNeilS.E.Unique benefits of nanotechnology to drug delivery and"/>
  <result pre="protein nanoparticles induce coronavirus neutralizing antibodies in miceVaccine2014323169317410.1016/j.vaccine.2014.04.01624736006 124.LiuY.V.MassareM.J.BarnardD.L.KortT.NathanM.WangL.SmithG.Chimeric severe" exact="acute" post="respiratory syndrome coronavirus (SARS-CoV) S glycoprotein and influenza matrix"/>
  <result pre="nanoparticles induce coronavirus neutralizing antibodies in miceVaccine2014323169317410.1016/j.vaccine.2014.04.01624736006 124.LiuY.V.MassareM.J.BarnardD.L.KortT.NathanM.WangL.SmithG.Chimeric severe acute" exact="respiratory" post="syndrome coronavirus (SARS-CoV) S glycoprotein and influenza matrix 1"/>
  <result pre="induce coronavirus neutralizing antibodies in miceVaccine2014323169317410.1016/j.vaccine.2014.04.01624736006 124.LiuY.V.MassareM.J.BarnardD.L.KortT.NathanM.WangL.SmithG.Chimeric severe acute respiratory" exact="syndrome" post="coronavirus (SARS-CoV) S glycoprotein and influenza matrix 1 efficiently"/>
  <result pre="particle mimetic nanovesicles displaying the S protein of Middle East" exact="respiratory" post="syndrome coronavirus using insect cellsJ. Biotechnol.201930617718410.1016/j.jbiotec.2019.10.00731614169 127.Sanchez-GuzmanD.Le GuenP.VilleretB.SolaN.Le BorgneR.GuyardA.KemmelA.CrestaniB.SallenaveJ.M.Garcia-VerdugoI.Silver"/>
  <result pre="mimetic nanovesicles displaying the S protein of Middle East respiratory" exact="syndrome" post="coronavirus using insect cellsJ. Biotechnol.201930617718410.1016/j.jbiotec.2019.10.00731614169 127.Sanchez-GuzmanD.Le GuenP.VilleretB.SolaN.Le BorgneR.GuyardA.KemmelA.CrestaniB.SallenaveJ.M.Garcia-VerdugoI.Silver nanoparticle-adjuvanted"/>
  <result pre="Biotechnol.201930617718410.1016/j.jbiotec.2019.10.00731614169 127.Sanchez-GuzmanD.Le GuenP.VilleretB.SolaN.Le BorgneR.GuyardA.KemmelA.CrestaniB.SallenaveJ.M.Garcia-VerdugoI.Silver nanoparticle-adjuvanted vaccine protects against lethal influenza" exact="infection" post="through inducing BALT and IgA-mediated mucosal immunityBiomaterials201921711930810.1016/j.biomaterials.2019.11930831279103 128.YeS.ShaoK.LiZ.GuoN.ZuoY.LiQ.LuZ.ChenL.HeQ.HanH.Antiviral Activity"/>
  <result pre="Mater. Interfaces20157215712157910.1021/acsami.5b0687626370151 129.DuT.LuJ.LiuL.DongN.FangL.XiaoS.HanH.Antiviral Activity of Graphene Oxideâ€&quot;Silver Nanocomposites by Preventing" exact="Viral" post="Entry and Activation of the Antiviral Innate Immune ResponseACS"/>
  <result pre="in vaccinationJ. Biosci.200934995100310.1007/s12038-009-0114-320093753 145.ZhaoL.SethA.WibowoN.ZhaoC.-X.MitterN.YuC.MiddelbergA.P.J.Nanoparticle vaccinesVaccine20143232733710.1016/j.vaccine.2013.11.06924295808 146.KerryR.G.MalikS.ReddaY.T.SahooS.PatraJ.K.MajhiS.Nano-based approach to combat emerging" exact="viral" post="(NIPAH virus) infectionNanomed. Nanotechnol. Biol. Med.20191819622010.1016/j.nano.2019.03.00430904587 147.ShaligramS.CampbellA.Toxicity of copper"/>
  <result pre="delivery systemAquaculture201951273437710.1016/j.aquaculture.2019.734377 149.SinghL.KrugerH.G.MaguireG.E.M.GovenderT.ParboosingR.The role of nanotechnology in the treatment of" exact="viral" post="infectionsAdv. Infect. Dis.2017410513110.1177/204993611771359328748089 150.DormontF.BrusiniR.CailleauC.ReynaudF.PeramoA.GendronA.MouginJ.GaudinF.VarnaM.CouvreurP.Squalene-based multidrug nanoparticles for improved mitigation"/>
  <result pre="infectionsAdv. Infect. Dis.2017410513110.1177/204993611771359328748089 150.DormontF.BrusiniR.CailleauC.ReynaudF.PeramoA.GendronA.MouginJ.GaudinF.VarnaM.CouvreurP.Squalene-based multidrug nanoparticles for improved mitigation of" exact="uncontrolled" post="inflammationSci. Adv.2020eaaz546610.1126/sciadv.aaz546632548259 Figure 1 Types of common viral infections,"/>
  <result pre="mitigation of uncontrolled inflammationSci. Adv.2020eaaz546610.1126/sciadv.aaz546632548259 Figure 1 Types of common" exact="viral" post="infections, the details are obtained from Ref. [9]. Figure"/>
  <result pre="COVID-19. Reproduced (adapted) with permission from [71]. Copyright Â© 2020," exact="American" post="Chemical Society. Figure 5 The onset of the clinical"/>
  <result pre="against massive outbreaks. Ad4, 5, or 26 vectors (human adenovirus" exact="type 4," post="5, or 26); ChAd (chimpanzee adenovirus); MVA (modified vaccinia"/>
  <result pre="type 4, 5, or 26); ChAd (chimpanzee adenovirus); MVA (modified" exact="vaccinia" post="Ankara); VSV (vesicular stomatitis virus); HPIV3 (human parainfluenza virus"/>
  <result pre="26); ChAd (chimpanzee adenovirus); MVA (modified vaccinia Ankara); VSV (vesicular" exact="stomatitis" post="virus); HPIV3 (human parainfluenza virus type 3); MV (measles"/>
  <result pre="of explored vaccines against CoV, based on various viruses or" exact="viral" post="parts. Redrawn from [73]. The details are obtained from"/>
  <result pre="(a) inhibition of protein S receptor interface, (b) inhibition of" exact="viral" post="RNA genome replication. Redrawn with permission from [57]. Copyright"/>
  <result pre="genome replication. Redrawn with permission from [57]. Copyright Â© 2020," exact="American" post="Chemical Society. Figure 9 Biosensor design representation: (A) zirconium"/>
  <result pre="developed nanoparticulate drug delivery systems towards treatment and/or therapy of" exact="viral" post="infections. Nanoplatform Properties (Shape/Size/Toxicity) Drug Virus Refs. NPs Silver"/>
  <result pre="Virus Refs. NPs Silver (Ag) Monodisperse and uniformly spherical; highly" exact="stable" post="Ag@AM (2 nm &amp;gt; 28 days); Ag NPs loaded"/>
  <result pre="HPAC 99% drug loading efficiency; HPAC (diverse concentrations)â€&quot;non-cytotoxic towards human" exact="epithelial" post="cells (vaginal, corneal), foreskin fibroblasts, HeLa cells: cell viability"/>
  <result pre="Chiral gold NPs-quantum dot (QD) nanocomposites CoVs Chiral plasmonâ€&quot;exciton systems" exact="Viral" post="detection [47] Graphene oxide (GO) sheets Feline CoVs Organism"/>
  <result pre="Feline CoVs Organism models: fcwf-4 cells, DF-1 cells; association with" exact="viral" post="lipid tails leading to aggregation and rupture of the"/>
  <result pre="lipid tails leading to aggregation and rupture of the envelop" exact="Viral" post="inhibition [48] GO sheets with silver particles Feline CoVs"/>
  <result pre="[48] GO sheets with silver particles Feline CoVs Association with" exact="viral" post="lipid tails leading to aggregation with attachment of silver"/>
  <result pre="with â€&quot;SH group of protein and rupture of the envelop" exact="Viral" post="inhibition [48] Carbon electrodes modified with gold NPs MERS"/>
  <result pre="for a fixed concentration of added antibody to the sample" exact="Viral" post="detection [49] Gold NPâ€&quot;adjuvanted S protein SARS-CoVs Stimulates significant"/>
  <result pre="protein SARS-CoVs Stimulates significant antigenâ€&quot;specific IgG response against SARSâ€&quot;related CoV" exact="infection" post="Development of vaccines against severe pneumoniaâ€&quot;associated CoVs [50] Cationic"/>
  <result pre="[50] Cationic carbon dots based on curcumin CoVs; porcine epidemic" exact="diarrhea" post="virus (PEDV) Inhibition of the viral proliferation; the structure"/>
  <result pre="curcumin CoVs; porcine epidemic diarrhea virus (PEDV) Inhibition of the" exact="viral" post="proliferation; the structure of surface protein in viruses has"/>
  <result pre="of surface protein in viruses has been changed, thus prohibiting" exact="viral" post="entry; cationic carbon dots based on curcumin can suppress"/>
  <result pre="of reactive oxygen species by virus. Further, it can suppress" exact="viral" post="replication by stimulating the formation of interferon-stimulating genes (ISGs)"/>
  <result pre="model of CoV Ag2S NCs treatment prohibited the formation of" exact="viral" post="negative-strand RNA and viral budding. It positively regulated the"/>
  <result pre="NCs treatment prohibited the formation of viral negative-strand RNA and" exact="viral" post="budding. It positively regulated the production of IFN-stimulating genes"/>
  <result pre="and the expression of pro-inflammation cytokines, which may inhibit the" exact="virus infection;" post="inhibition of CoV proliferation Viral inhibition [52] Chiral zirconium"/>
  <result pre="which may inhibit the virus infection; inhibition of CoV proliferation" exact="Viral" post="inhibition [52] Chiral zirconium QDs CoVs The fluorescence properties"/>
  <result pre="zirconium QDs CoVs The fluorescence properties of immuno-conjugated QD-magneto-plasmonic NPs" exact="Viral" post="detection [53] nanomaterials-10-01072-t003_Table 3Table 3 Some important Au NP-based"/>
  <result pre="25 nM, 50âˆ’25 nM ND Fluorometric HA antigen Spherical, 25" exact="Protein" post="A Fluorometric 13.9 pg/mL, 800âˆ’12.5 ng/mL ND M k"/>
  <result pre="A; d five-prime untranslated region; e core; f surface; g" exact="hepatitis" post="B antigen; h dynamic light scattering; i localized surface"/>
  <result pre="surface; g hepatitis B antigen; h dynamic light scattering; i" exact="localized" post="surface plasmon resonance; j surface enhanced Raman scattering; k"/>
  <result pre="TGEV Gold NPs Gold NPs Acceleration of the peritoneal macrophages" exact="respiratory" post="activity and plasma IFN-Î³ level [84] SARS-CoV Gold NPs"/>
  <result pre="humoral responses and IgG2a antibodies, with no stimulation in lung" exact="eosinophilic" post="immunopathology [86] MERS-CoV Spike protein NPs Aluminum Stimulation of"/>
  <result pre="Summary of diverse types of nanocarrier/NP-based vaccine delivery systems against" exact="viral" post="infections. Nanocarriers Delivery System Virus Antigen/Adjuvant Disease Route of"/>
  <result pre="delivery systems against viral infections. Nanocarriers Delivery System Virus Antigen/Adjuvant" exact="Disease" post="Route of Administration Refs. Gold NPs HIV-1 Viral plasmid"/>
  <result pre="Virus Antigen/Adjuvant Disease Route of Administration Refs. Gold NPs HIV-1" exact="Viral" post="plasmid DNA HIV/AIDS pandemic Intradermal [90] Gold NPs H1N1"/>
  <result pre="Route of Administration Refs. Gold NPs HIV-1 Viral plasmid DNA" exact="HIV/AIDS" post="pandemic Intradermal [90] Gold NPs H1N1 Membrane matrix protein"/>
  <result pre="protein 2 (M2e)/CpG Influenza Intranasal [91] Gold NPs FMDV a" exact="Viral" post="protein Foot and mouth disease Intradermal [92] Gold NPs"/>
  <result pre="[91] Gold NPs FMDV a Viral protein Foot and mouth" exact="disease" post="Intradermal [92] Gold NPs H1N1, H3N2, H5N1 M2e/CpG Influenza"/>
  <result pre="H5N1 M2e/CpG Influenza Intranasal [93] Chitosan NPs HBV b HBsAg" exact="Hepatitis" post="B Intraperitoneal [94] Carbon magnetic NPs - Hen egg"/>
  <result pre="- Intravenous [95] Chitosan NPs NV c Live virus vaccine" exact="Newcastle disease" post="Intranasal or oral [96] PCL d/chitosan NPs HBV HBsAg"/>
  <result pre="Intravenous [95] Chitosan NPs NV c Live virus vaccine Newcastle" exact="disease" post="Intranasal or oral [96] PCL d/chitosan NPs HBV HBsAg"/>
  <result pre="disease Intranasal or oral [96] PCL d/chitosan NPs HBV HBsAg" exact="Hepatitis" post="B Intranasal [97] Î³-PGA NPs H1N1 Hemagglutinin (HA) Influenza"/>
  <result pre="Hemagglutinin (HA) Influenza Intranasal [98] VLPs NV Capsid protein Norwalk" exact="virus infection" post="Oral [88] VLPs HBV Nucleocapsid protein Hepatitis Intravenous [89]"/>
  <result pre="(HA) Influenza Intranasal [98] VLPs NV Capsid protein Norwalk virus" exact="infection" post="Oral [88] VLPs HBV Nucleocapsid protein Hepatitis Intravenous [89]"/>
  <result pre="protein Norwalk virus infection Oral [88] VLPs HBV Nucleocapsid protein" exact="Hepatitis" post="Intravenous [89] VLPs H3N2 Structural proteins, e.g., HA, neuraminidase,"/>
  <result pre="[88] VLPs HBV Nucleocapsid protein Hepatitis Intravenous [89] VLPs H3N2" exact="Structural" post="proteins, e.g., HA, neuraminidase, NA, and matrix (M1) Influenza"/>
  <result pre="and matrix (M1) Influenza Intramuscular [99] VLPs RV e 8-2/6/7-VLP" exact="Multiple" post="proteins, e.g., cholera toxin (CT) and Escherichia coli heat-labile"/>
  <result pre="Influenza Intramuscular [99] VLPs RV e 8-2/6/7-VLP Multiple proteins, e.g.," exact="cholera" post="toxin (CT) and Escherichia coli heat-labile toxin (LT) Rotavirus"/>
  <result pre="coli heat-labile toxin (LT) Rotavirus Rectal [100] Polypeptide NPs CoV" exact="Viral" post="protein (spike) SARS-CoV - [101] Alginate coated chitosan NPs"/>
  <result pre="(spike) SARS-CoV - [101] Alginate coated chitosan NPs HBV HBsAg" exact="Hepatitis" post="B Intranasal [102] PLA and PLGA NPs HBV Hepatitis"/>
  <result pre="HBsAg Hepatitis B Intranasal [102] PLA and PLGA NPs HBV" exact="Hepatitis" post="B surface antigen Hepatitis B Pulmonary or intramuscular [103]"/>
  <result pre="[102] PLA and PLGA NPs HBV Hepatitis B surface antigen" exact="Hepatitis" post="B Pulmonary or intramuscular [103] PLA and PLGA nano/micropraticles"/>
  <result pre="and PLGA NPs HBV Hepatitis B surface antigen Hepatitis B" exact="Pulmonary" post="or intramuscular [103] PLA and PLGA nano/micropraticles TT f"/>
  <result pre="toxoid Tetanus Intramuscular [104] PLGA NPs BPI3V g BPI3V proteins" exact="Bovine" post="respiratory Intranasal [105] Polyanhydride RSV F and G glycoproteins"/>
  <result pre="Tetanus Intramuscular [104] PLGA NPs BPI3V g BPI3V proteins Bovine" exact="respiratory" post="Intranasal [105] Polyanhydride RSV F and G glycoproteins Bovine"/>
  <result pre="Bovine respiratory Intranasal [105] Polyanhydride RSV F and G glycoproteins" exact="Bovine" post="respiratory syncytial Intranasal [106] HPMA/NIPAM h RSV F protein/TLR-7/8"/>
  <result pre="respiratory Intranasal [105] Polyanhydride RSV F and G glycoproteins Bovine" exact="respiratory" post="syncytial Intranasal [106] HPMA/NIPAM h RSV F protein/TLR-7/8 agonist"/>
  <result pre="[109] Cationic nanomicelles based on PSA k HIV-1 PSA/mRNA encoding" exact="HIV/AIDS" post="- [110] a Foot-and-mouth disease virus; b hepatitis B"/>
  <result pre="PSA k HIV-1 PSA/mRNA encoding HIV/AIDS - [110] a Foot-and-mouth" exact="disease" post="virus; b hepatitis B virus; c Newcastle virus; d"/>
  <result pre="PSA/mRNA encoding HIV/AIDS - [110] a Foot-and-mouth disease virus; b" exact="hepatitis" post="B virus; c Newcastle virus; d poly-Îµ-caprolactone; e Rotavirus;"/>
  <result pre="B virus; c Newcastle virus; d poly-Îµ-caprolactone; e Rotavirus; f" exact="tetanus" post="toxoid; g bovine parainfluenza 3 virus; h N-(2-hydroxypropyl)methacrylamide/N-isopropylacrylamide; i"/>
 </snippets>
</snippetsTree>
